Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 278, Issue 4 47-4, 2000, Pages

  Xiao, Qiang ^a   Boushey, Robin P ^a   Cino, Maria ^a   Drucker, Daniel J ^a,b   Brubaker, Patricia L ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Crohn's disease; Intestine; Short bowel syndrome; Ulcerative colitis

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; ENZYME ACTIVITY; FEMALE; HUMAN; INTESTINE ADAPTATION; INTESTINE MUCOSA; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SHORT BOWEL SYNDROME; ULCERATIVE COLITIS;

EID: 0033998750     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.2000.278.4.r1057     Document Type: Article

References (32)

1. Bloom SR and Polak JM. The hormonal pattern of intestinal adaptation [a major role for enteroglucagon]. Scand J Gastroenterol 17: 93-103, 1982.
2. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai C-H, and Drucker DJ. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 138: 4837-4843, 1997.
3. Brubaker PL, Izzo A, Hill M, and Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol Endocrinol Metab 272: E1050-E1058, 1997.
4. Chance WT, Zhang X, Balasubramaniam A, and Fischer JE. Preservation of intestine protein by peptide YY during total parenteral nutrition. Life Sci 58: 1785-1794, 1996.
5. Chu KU, Higashide S, Evers BM, Ishizuka J, Townsend CM Jr, and Thompson JC. Bombesin stimulates mucosal growth in jejunal and ileal Thiry-Vella fistulas. Ann Surg 221: 602-611, 1995.
6. Chung DH, Evers BM, Shimoda I, Townsend CM Jr, Rajaraman S, and Thompson JC. Effect of neurotensin on gut mucosal growth in rats with jejunal and ileal Thiry-Vella fistulas. Gastroenterology 103: 1254-1259, 1992.
7. Deacon CF, Johnsen AH, and Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957, 1995.
8. Drucker DJ. The glucagon-like peptides. Diabetes 47: 159-169, 1998.
9. Drucker DJ. Intestinal growth factors. Am J Physiol Gastrointest Liver Physiol 273: G3-G6, 1997.
10. Drucker DJ, Ehrlich P, Asa SL, and Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93: 7911-7916, 1996.
11. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, Deforest L, Cooper S, and Brubaker PL. Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV. Nat Biotechnol 15: 673-677, 1997.
12. Egger B, Carey HV, Procaccino F, Chai N-N, Sandgren EP, Lakshmanan J, Buslon VS, French QW, Buchler MW, and Eysselein VE. Reduced susceptibility of mice overexpressing transforming growth factor α to dextran sodium sulphate colitis. Gut 43: 64-70, 1998.
13. Egger B, Procaccino F, Lakshmanan J, Reinshagen M, Hoffman P, Patel A, Reuben W, Gnanakkan S, Liu L, Barajas L, and Eysselein VE. Mice lacking transforming growth factor α have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology 113: 825-832, 1997.
14. Gleeson MH, Bloom SR, Polak JM, Henry K, and Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 12: 773-782, 1971.
15. Hanauer SB. Inflammatory bowel disease. N Engl J Med 334: 841-848, 1996.
16. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, and Orskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 269: 18827-18833, 1994.
17. Howarth GS, Xian CJ, and Read LC. Insulin-like growth factor-I partially attenuates colonic damage in rats with experimental colitis induced by oral dextran sulphate sodium. Scand J Gastroenterol 33: 180-190, 1998.
18. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, and Mortensen PB. Impaired meal-stimulated glucagon-like peptide-2 response in ileal resected short bowel patients with intestinal failure. Gut 45: 559-563, 1999.
19. Kieffer TJ, McIntosh CHS, and Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
20. Mashimo H, Wu D-C, Podolsky DK, and Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274: 262-265, 1996.
21. Patzelt C and Schlitz E. Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences. Proc Natl Acad Sci USA 81: 5007-5011, 1984.
22. Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulson R, Hanby AM, and Wright NA. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 93: 2137-2142, 1996.
23. Podolsky DK. Healing the epithelium: solving the problem from two sides. J Gastroenterol 32: 122-126, 1997.
24. Podolsky DK. Regulation of intestinal epithelial proliferation: a few answers, many questions. Am J Physiol Gastrointest Liver Physiol 264: G179-G186, 1993.
25. Roberge JN and Brubaker PL. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 128: 3169-3174, 1991.
26. Stevens FM, Flanagan RW, O'Gorman D, and Buchanan KD. Glucagonoma syndrome demonstrating giant duodenal villi. Gut 25: 784-791, 1984.
27. Taylor RG, Beveridge DJ, and Fuller PJ. Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection. Biochem J 286: 737-741, 1992.
28. Taylor RG and Fuller PJ. Humoral regulation of intestinal adaptation. Baillieres Clin Endocrinol Metab 8: 165-183, 1994.
29. Tsai C-H, Hill M, Asa SL, Brubaker PL, and Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol Endocrinol Metab 273: E77-E84, 1997.
30. Ulshen MH, Hoyt EC, Fuller CR, Ghatei MA, Bloom SR, and Lund PK. Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth. Dig Dis Sci 41: 677-683, 1996.
31. Xiao Q, Boushey RP, Drucker DJ, and Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117: 99-105, 1999.
32. Zeeh JM, Procaccino F, Hoffmann P, Aukerman SL, McRoberts JA, Soltani S, Pierce GF, Lakshmanan J, Lacey D, and Eysselein VE. Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 110: 1077-1083, 1996.